AGC
PCRX icon

Alden Global Capital’s Pacira BioSciences PCRX Stock Holding History

Alden Global Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-61,287
Closed -$1.98M – 10
2016
Q4 		$1.98M Buy
+61,287
New +$2.05M 0.68% 5

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alden Global Capital's PCRX Position: Q1 2017 in Review

Alden Global Capital sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 61,287 shares — an estimated $1.98M sold.

Alden Global Capital first reported a position in PCRX in Q4 2016 and held it in 1 quarter. The position peaked at $1.98M in Q4 2016. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

  • Alden Global Capital reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
  • Alden Global Capital sold 61,287 Pacira BioSciences shares in Q1 2017, an estimated $1.98M.
  • Alden Global Capital first reported a position in Pacira BioSciences in Q4 2016 and held it in 1 quarter.
  • Alden Global Capital's Pacira BioSciences position peaked at $1.98M in Q4 2016.
  • 192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Alden Global Capital's 13F filing for Q1 2017, filed 11 May 2017.